Shares of Merck & Co. Inc. MRK slid 1.81% to $88.05 Thursday, on what proved to be an all-around mixed trading session for ...

Merck (MRK) is down -10.1%, or -$10.10 to $89.69. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended ...

In a report released today, Richard Vosser from J.P. Morgan maintained a Buy rating on Merck KGaA (0O14 – Research Report), with a price target ...

Co., Inc. (NYSE:MRK), recently purchased 2,832.861 shares of the company's common stock. The acquisition, valued at approximately $249,999, was completed at a price of $88.25 per share. Following this ...

Chief Communications and Public Affairs Officer Cristal N. Downing recently sold shares of the company, according to a filing with the Securities and Exchange Commission. On February 6, 2025, Downing ...

The continued decline of Merck & Co.’s HPV vaccine Gardasil in China has come to a head as the New Jersey drug giant is halting shipments to the world’s second-most populous country.

For the recently completed fourth quarter, Merck booked an adjusted profit of $1.72 per share on $15.6 billion in revenue. Sales of top-selling cancer treatment Keytruda climbed 19% to $7.84 billion.

Merck’s Q4 sales rose 7% YoY to $15.62B, slightly beating the $15.49B consensus. Adjusted EPS jumped to $1.72, topping estimates of $1.62. Keytruda sales grew 19% YoY to $7.84B, while Gardasil ...

Shares of Merck slid Tuesday after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales forecast due partly to a pause in shipments of one of its top-selling products to China.

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Merck shares tumbled after the drugmaker said it was halting shipments of a top-selling vaccine to China to ...

Merck achieved revenue growth in Q4, but stocks tumbled Tuesday amid news that the company is pausing Gardasil shipments to China. © 2024 Fortune Media IP Limited ...

The pause announcement comes a month after Merck received approval in China for use of the vaccine in males. “We believe China still represents a significant, long-term opportunity for Gardasil ...